Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.


Related Content

Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
Watson Hopes Accelerated Approval For Progesterone Gel Remains Option
NeurogesX’s Qutenza Potential For Successful Committee Review Hinges On Post Hoc Efficacy Analyses
Columbia/Watson’s Progesterone Gel For Preterm Births Needs Additional Studies, Advisory Panel Says
K-V Gets FDA To Test Adequacy Of Makena’s Competing Compounded Products
Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?
KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval
Columbia Labs' Prochieve Could Address $150 Million To $300 Million Preterm Birth Market
Columbia’s Prochieve Could Get Competitive Edge From Committee Review Of Rival Product


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts